ArticleFrontiers in molecular biosciences2025
Targeted urinary metabolomics combined with machine learning to identify biomarkers related to central carbon metabolism for IBD.
Article in Frontiers in molecular biosciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Urinary Organic Acid Profiling by GC-MS Reveals Distinct Metabolic Signatures for Non-Invasive Diagnosis and Disease Activity Monitoring of Inflammatory Bowel Disease.International journal of molecular sciences · 2026Article
- Oxidative-Stress-Associated Molecular Signatures in Immune-Mediated Diseases: A Systematic Review Integrating Machine Learning and Systems Biology Approaches.Antioxidants (Basel, Switzerland) · 2026Review
- Crohn's disease: research progress in decoding pathogenic multi-network and precision management of artificial intelligence radiomics.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Inflammatory bowel disease (IBD), comprising Crohn's disease (CD) and ulcerative colitis (UC), is a chronic and relapsing inflammatory disorder of the gastrointestinal tract. Current diagnostic approaches are invasive, costly, and time-consuming, underscoring the need for non-invasive, accurate diagnostic methods. Methods: We conducted a targeted metabolomic analysis of 49 metabolites related to central carbon metabolism in urinary samples from individuals with IBD and control group. Diagnostic models were constructed using six machine learning algorithms, and their performance was evaluated by cross-validated area under the receiver operating characteristic curve (AUC). The SHAP (SHapley Additive exPlanations) method was used to interpret the models and identify key discriminatory features. Results: Six metabolites-xylose, isocitric acid, fructose, L-fucose, N-acetyl-D-glucosamine (GlcNAc), and glycolic acid-differentiated UC from control group, while three metabolites-xylose, L-fucose, and citric acid-distinguished CD from control group. The optimal diagnostic model achieved a mean AUC of 0.84 for UC and 0.93 for CD. These models retained high diagnostic accuracy even after adjusting for disease activity. SHAP analysis identified L-fucose, xylose, and GlcNAc as important features for UC, and citric acid and xylose for CD. Discussion: Our findings highlight distinct metabolic signatures in central carbon metabolism associated with IBD subtypes. The identified metabolite panels, combined with machine learning models, offer promising non-invasive tools for differentiating UC and CD from healthy individuals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.